The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy

Rationale: Head and neck squamous cell carcinoma (HNSCC) represent the 4(th) most aggressive cancer. 50% of patients relapse to the current treatments combining surgery, radiotherapy and cisplatin and die two years after the diagnosis. Elevated expression of the polo-like kinase 1 (Plk1) correlated...

Descripción completa

Detalles Bibliográficos
Autores principales: Hagege, Anais, Ambrosetti, Damien, Boyer, Julien, Bozec, Alexandre, Doyen, Jérôme, Chamorey, Emmanuel, He, Xingkang, Bourget, Isabelle, Rousset, Julie, Saada, Esma, Rastoin, Olivia, Parola, Julien, Luciano, Frederic, Cao, Yihai, Pagès, Gilles, Dufies, Maeva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8490521/
https://www.ncbi.nlm.nih.gov/pubmed/34646387
http://dx.doi.org/10.7150/thno.61711

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8490521/
https://www.ncbi.nlm.nih.gov/pubmed/34646387
http://dx.doi.org/10.7150/thno.61711

Ejemplares similares